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ABSTRACT 
Ataxia Telangiectasia and Rad3 related (ATR) is one of the main regulators of the DNA damage 
response. It coordinates cell cycle checkpoint activation, replication fork stability, restart and origin 
firing to maintain genome integrity. Mutations of the ATR gene have been reported in Seckel patients, 
who suffer from a rare genetic disease characterized by severe microcephaly and growth retardation. 
Here, we report the case of a Seckel patient with compound heterozygous mutations in ATR. One 
allele has an intronic mutation affecting splicing of neighbouring exons, the other an exonic missense 
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mutation, producing the variant p.Lys1665Asn, of unknown pathogenicity. We have modelled this 
novel missense mutation, as well as a previously described missense mutation p.Met1159Ile, and 
assessed their effect on ATR function. Interestingly, our data indicates that both missense mutations 
have no direct effect on protein function, but rather result in defective ATR splicing. These results 
emphasize the importance of splicing mutations in Seckel Syndrome. 
KEY WORDS 
ATR, Seckel syndrome, Splicing regulation, chicken 
Brief Report 
To maintain genomic integrity, eukaryotic cells have developed a conserved network of pathways of 
DNA damage sensing, signalling and repair, known as the DNA Damage Response (DDR). The 
Ataxia Telangiectasia mutated and Rad3-related (ATR) kinase functions as a master regulator of the 
DDR in response to the presence of single stranded DNA (ssDNA).  
Whilst ATR (NM_001184.3) is an essential gene in mammalian cells, hypomorphic mutations have 
been implicated in the development of Seckel Syndrome (MIM# 210600), a rare human disorder 
characterized by severe microcephaly, mental retardation and developmental defects. In 2003, 
O’Driscoll and colleagues first described a silent homozygous point mutation in exon 9 of ATR 
(c.2101A>G) in a single family, in which the affected patients exhibited a severe form of 
microcephalic primordial dwarfism (O'Driscoll et al., 2003). Subsequent analysis of this mutation 
revealed that it disrupted splicing between exons 9 and 10 of the ATR gene resulting in the generation 
of a premature stop codon. Nonetheless, a small amount of normal mRNA was produced at sufficient 
levels to maintain cell viability (O'Driscoll et al., 2003). Additional mutations in ATR were since 
linked to Seckel Syndrome (Mokrani-Benhelli et al., 2013; Ogi et al., 2012).  
In this study, we identified two novel compound heterozygous ATR mutations implicated in Seckel 
Syndrome (Patient P1
ATR
), one of which, c.151+4A>G
 
(NG_008951.1), is known to affect splicing, 
while c.4995G>T results in an amino acid change, p.Lys1665Asn, of undetermined pathogenicity. 
Here, we used chicken DT40 cells as a model system to characterise the impact of the p.Lys1665Asn 
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mutation on ATR protein function. Additionally, we modelled ATR protein function from the 
previously identified p.Met1159Ile missense variant of Patient 27-4BI (Ogi et al 2012). Interestingly, 
neither missense mutation significantly affects the function of the ATR protein. However, both exonic 
point mutations significantly perturb normal splicing of the ATR gene, indicating that ATR-Seckel 
Syndrome is primarily caused by mutations that affect gene splicing. 
Patient P1
ATR
 was born to healthy unrelated parents. Intra-uterine growth retardation was noted during 
the pregnancy. Following birth, the patient exhibited microcephaly, growth retardation and facial 
dysmorphia (Figure 1A, Supp. Figure S1). Whole exome sequencing of genomic DNA from patient 
P1
ATR
 identified two novel ATR mutations, which were verified by Sanger sequencing (Figure 1C, D). 
The maternal ATR allele of this compound heterozygous patient harboured a mutation in intron 2 
(c.151+4A>G), predicted to result in aberrant gene splicing leading to a frameshift at codon 52 and 
generation of a premature stop 27 bp downstream (p.Ala52Cysfs*9). The paternal ATR allele contains 
a point mutation located in exon 28 (c.4995G>T) resulting in an p.Lys1665Asn amino acid 
substitution of unknown pathogenicity (Figure 1C). 
Western blot analysis of a fibroblast cell line derived from patient P1
ATR
 confirmed a reduction in 
total ATR protein expression (Figure 1B), as previously observed in cell lines derived from other 
Seckel Syndrome patients (Mokrani-Benhelli et al., 2013; O'Driscoll et al., 2003; Ogi et al., 2012). 
Assessment of DDR activation in cells from patient P1
ATR
 showed a reduction in UV-induced Chk1 
phosphorylation (Figure 1E). Consistent with the increased replication stress that is usually seen in 
cells with defective ATR signalling, cells from patient P1
ATR
 exhibited elevated levels of RPA2 and 
H2AX phosphorylation following the exposure to UV (Figure 1E). However, the DNA damage-
induced phosphorylation of SMC1 and NBS1 in fibroblasts from this patient were relatively 
unaffected, suggesting that the residual ATR protein retains some normal level of activity towards 
specific downstream substrates ??? (Figure 1B, E). 
Given that both patients (P1
ATR
 and 27-4BI) harbour distinct missense mutations (p.Met1159Ile and 
p.Lys1665Asn), we tested the effects of these mutations on ATR signalling. To study the 
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p.Met1159Ile and p.Lys1665Asn Seckel mutations we initially used our previously published chicken 
DT40 Atr conditional null cell line (Eykelenboom et al., 2013). For this cell line, the equivalent amino 
acids of the mutated human residues correspond to positions p.Met1180 and p.Lys1685 in the chicken 
Atr sequence (Figure 1F). Both of these residues are located within regions that are highly conserved 
between human ATR and chicken Atr suggesting that these residues could be important for ATR 
function. 
We generated and separately targeted Atr p.Met1180Ile and Atr p.Lys1685Asn cDNA constructs to 
the Ovalbumin (Ova) locus of AID-Atr conditional-null DT40 cells (Suppl. Figure S2A, C). Southern 
blotting confirmed successful targeting of these constructs in AID-Atr DT40 cells (Suppl. Figure 
S2B).  
Since all ATR Seckel hypomorphic mutations previously described result in very low levels of protein 
expression (Mokrani-Benhelli et al., 2013; O'Driscoll et al., 2003; Ogi et al., 2012), we first examined 
whether Atr p.Met1180Ile and Atr p.Lys1685Asn mutations caused a reduction in protein stability. 
Interestingly, the missense Atr Seckel mutations had no effect on protein stability in our DT40 system, 
with both mutant Atr proteins being expressed comparably to the WT control (Figure 1G). 
Next, we investigated whether the Atr p.Met1180Ile and Atr p.Lys1685Asn mutations affected cell 
proliferation. We analysed proliferation by counting cells every 24h in the presence and absence of 
auxin (IAA) in the media. Neither Atr p.Met1180Ile nor Atr p.Lys1685Asn mutated cells displayed 
proliferation deficiencies compared to the WT control (Figure 1H). 
To explore the effect of these mutations in the DT40 system more carefully, we assessed whether the 
mutant cell lines were able to activate ATR in response to hydroxyurea (HU). HU indirectly causes 
replication fork stalling by depleting the intra-cellular concentration of nucleotides, and ATR 
activation can be measured by assessing the phosphorylation of Chk1. Our results show that DT40 
cells containing Atr p.Met1180Ile or Atr p.Lys1685Asn as their sole source of full-length Atr protein 
are still able to phosphorylate Chk1 at serine 345 (Figure 1I). We also confirmed normal Atr-
dependent signalling by analysing HU-induced apoptosis (Figure 1J). While loss of functional Atr 
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results in increased apoptosis upon HU treatment (AID-Atr control treated with both AUX and HU), 
the presence of the Atr p.Met1180Ile and Atr p.Lys1685Asn proteins prevented cells from entering 
apoptosis. 
Our data, obtained using chicken Atr cDNA expressed in DT40 cells to model human hypomorphic 
ATR mutations, suggests that that the ATR p.Met1159Ile and ATR p.Lys1665Asn missense mutations 
found in Seckel patients do not affect the function of the ATR protein. This implies that the 
underlying pathology of these missense mutations might not be related to protein function. However, 
we cannot exclude the possibility that the missense point mutations destabilise ATR specifically in 
human cells. 
As the Atr p.Met1180Ile and Atr p.Lys1685Asn mutations displayed no effect on Atr function in 
DT40 cells, we considered the possibility that the equivalent human mutations (ATR p.Met1159Ile 
and ATR p.Lys1665Asn) may affect splicing by abrogating a splicing enhancer or generating a 
splicing silencer within their respective exonic sequences. Thus, the phenotype of both mutations 
could result from exon skipping, rather than from the encoded amino acid change.  Therefore, we 
directly assessed the splicing of exons 18 and 28 in human lymphoblasts (LCLs) derived from 
patients. Shorter splice variants of the expected sizes were detected by RT-PCR in both patient 
samples (Figure 2A). In addition, we were still able to detect normally spliced ATR, which either 
corresponds to the equivalent regions of the transcripts from the second ATR allele in each patient or 
to leaky splice mutations. DNA sequencing confirmed that the smaller PCR products correspond to 
the exon-skipped variants (Figure 2B). In these transcripts either exons 17 and 19 or 27 and 29 are 
spliced together, resulting in a frameshift and the subsequent generation of a downstream premature 
stop codon (Supp. Figure S3C,D). These truncated forms of the ATR protein (Supp. figure S3A-E) 
were not detected by Western blotting (data not shown), suggesting that the resulting proteins are 
either not expressed or unstable. In fact, using cycloheximide to prevent nonsense mediated decay 
(NMD) of mRNAs with premature stop codons we could establish that skipping of exon 28 from 
patient P1
ATR
 results in NMD.  On the other hand, we could find no evidence for NMD of the mRNA 
corresponding to skipping of exon 18 from patient 27-4BI.    
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To confirm exon skipping seen in patient-derived LCLs, we used an in vivo splicing assay based on a 
mini-gene system previously used to investigate splicing regulation of other DDR genes, such as ATM 
and BRCA1 (Raponi et al., 2014). In this in vivo splicing assay, a plasmid containing the α-globin 
gene under a strong promoter was used (Supp. Figure S3F). The genomic region of interest was 
inserted within exon 3 of the α-globin gene and this plasmid was then transiently transfected into cells 
to examine splicing in vivo.  
We performed our experiments with the control Neurofibromin (NF1) mini-gene obtained from Diana 
Baralle’s laboratory (REF insert here????). To analyse the effect of ATR c.3477G>T and ATR 
c.4995G>T mutations on exon 18 and 28, respectively, we cloned these exons and flanking intronic 
regions into the NdeI sites of the NF1 plasmid (Supp. figure S3F). WT and mutant plasmids were 
transfected into both HeLa and HEK293T cells and RT-PCR was used to assess splicing (Figure 2C). 
Although the splicing defects observed in this mini-gene assay were not as striking as those observed 
in patient cells, we could detect shorter splice variants. These shorter variants corresponded to 
skipping of either exon 18 or exon 28 in the presence of the ATR c.3477G>T and ATR c.4995G>T 
mutations, respectively (Figure 2D). 
The Human Splicing Finder (HSF) and SFmap online tools predicted that both mutations, ATR 
c.3477G>T and ATR c.4995G>T, could potentially disrupt a binding site for the 9G8 splicing factor 
within ATR exons 18 and 28, respectively, while potential sites for splicing silencing factors 
SF2/ASF, hnRNP A1 and Tra2Beta might be created or lost by the presence of the mutations (Supp. 
Table S6).  
Using a previously described 5’ end-labelled RNA oligonucleotide probe specific to the 9G8 splicing 
factor (Gao et al., 2007) and unlabelled competitor RNA oligonucleotides corresponding to WT or 
mutant sequences from ATR exons 18 and 28, we assessed 9G8 binding in electrophoretic mobility 
shift assays (Figure 2E). Binding of 9G8 was easily detectable and readily competed by an excess of 
unlabelled 9G8 probe (Figure 2E, lane 1-3). While the WT ATR exon 18 probe did not compete, clear 
competition was observed when a 1000-fold molar excess of the mutant ATR exon 18 probe 
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(c.3477G>T) was used as a competitor (Figure 2E, lane 7). Thus, the c.3477G>T mutation generates a 
sequence capable of binding the 9G8 splicing factor more efficiently than the WT sequence (Figure 
2E). However, in this electrophoretic mobility shift assay, the WT and the mutant competitor RNA 
oligonucleotides derived from ATR exon 28 were indistinguishable (Figure 2F). Thus, the ATR 
c.4995G>T mutation in exon 28 does not have any specific impact upon binding of the 9G8 splicing 
factor and most likely affects a different splice factor not assessed by the 9G8 bandshift assay.  
Seckel Syndrome is a rare genetic disease caused by mutations in several genes, including ATR 
(Mokrani-Benhelli et al., 2013; O'Driscoll et al., 2003; Ogi et al., 2012). In this work, we have 
characterised two novel compound heterozygous ATR mutations in a Seckel Syndrome patient. In one 
patient, the maternally-derived allele harboured a novel intronic mutation in one allele (c.151+4A>G), 
which is predicted to affect ATR splicing; while the second paternal allele carried a missense mutation 
(c.4995G>T, encoding p.Lys1665Asn) of unknown pathogenicity. However, when we modelled this 
mutation, along with another Seckel-associated missense mutation (c.3477G>T, encoding 
p.Met1159Ile) in DT40 cells (Eykelenboom et al., 2013) we found that both Atr missense mutations 
were fully functional. These findings suggested that the missense mutations found in these Seckel 
patients do not exert their pathology by compromising ATR protein function. 
It has previously been shown that the classic ATR Seckel mutation (c.2101A>G), which is located 
within an exon, does not cause an amino acid substitution, but instead affects splicing. The resulting 
exon skipping in turn results in a frameshift and consequent premature termination of translation 
(O'Driscoll et al., 2003). In a similar case, a French patient with a mutation in exon 33 of ATR was 
predicted to disrupt a splicing enhancer (Mokrani-Benhelli et al., 2013). Following this trend, it is 
important to establish whether novel ATR Seckel missense mutations, in fact, disrupt the balance 
between different splicing regulatory elements. Sequences within exons (and introns) are required for 
successful splicing reactions and loss of these binding sites for a factor that enhances splicing or 
gaining a site for a factor that silences splicing would be predicted to result in exon skipping (Wang & 
Burge, 2008). 
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Therefore, we used human cells derived from patients to further investigate whether the missense 
mutations c.3477G>T and c.4995G>T (encoding for p.Met1159Ile and p.Lys1665Asn) also affected 
splicing. Both missense mutations resulted in exon skipping of exons 18 or 28, respectively, in both 
patient-derived cell lines and when modelled in an ectopic mini-gene based splicing assay. Thus, our 
results suggest that while both c.3477G>T and c.4995G>T Seckel mutations alter the amino acid 
sequence, pathologically they affect mRNA splicing rather than ATR protein function. While we have 
not fully elucidated the mechanisms behind this splicing deregulation, our in silico predictions and 
biochemical analysis suggest that these mutations might potentially disrupt splicing enhancers or 
silencers (Suppl. Table S6). In particular, when using HSF and SFmap online tools, it was predicted 
that both c.3477G>T and c.4995G>T mutations disrupt a binding site for 9G8 (Suppl. Material 2). 
9G8 belongs to the serine/arginine (SR) family, comprised of several splice factors known to play 
significant roles in constitutive as well as alternative splicing (Gao et al., 2007). Although SR proteins 
typically act as splicing activators by binding to exonic enhancers, studies show that in other contexts 
they can silence splicing (Shen et al., 2004). For example, the 9G8 factor studied here has been 
reported to promote exon 10 skipping of the Tau protein (Gao et al., 2007). This is reminiscent of our 
in vitro RNA binding studies, in which the c.3477G>T mutation in exon 18 appears to bind the 9G8 
splicing factor more effectively than the WT sequence. This data suggests that 9G8 binding 
suppresses normal splicing and results in exon 18 skipping. On the other hand, and despite the in 
silico predictions, we could not find any evidence that the c.4995G>T missense mutation in exon 28 
altered binding of 9G8, indicating that this mutation might affect splicing via a different mechanism 
(Figure 2F, Suppl. Material 2). In fact, in silico predictions also suggested that both ATR mutations 
could potentially create a silencer site recognized by the hnRNPA1, while another inhibitory site for 
Tra2Beta would also be generated in the presence of the c.4995G>T mutation in exon 28 (Suppl. 
Table S6). Further studies regarding these factors are necessary to fully understand how these 
mutations affect ATR splicing. 
Taken together, our data combined with previously published observations suggest that ATR-Seckel 
Syndrome is frequently caused by mutations, either exonic or intronic, that disrupt gene splicing. 
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Disease-related missense mutations are often assumed to directly affect protein function, for example, 
stability or cellular localisation. However, there is growing evidence that multiple human disorders 
caused by exonic mutations, irrespective of any amino change, are, in fact, the consequence of 
splicing defects (Baralle & Baralle, 2005; Lopez-Bigas et al., 2005). Interestingly, even nonsense 
mutations, which are commonly assumed to only disrupt protein function, by generating truncated 
isoforms, have been shown to cause splicing defects (Cartegni et al., 2002).  
As a result of exon skipping, both missense c.3477G>T and c.4995G>T mutations are predicted to 
cause a frameshift and the introduction of a premature stop codon. Our data is consistent with splicing 
mutations having a bigger impact than previously thought in human disorders (Li et al., 2016; Padgett, 
2012). Therefore, new diagnostic techniques, in which genomic screens coupled with whole 
transcriptome analysis are required to determine whether splicing defects rather than missense 
mutations underpin disease pathology. This will allow for the proper evaluation of how many human 
syndromes are caused by splicing mutations, which are currently likely to be underestimated. 
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FIGURE LEGENDS 
Figure 1. Characterisation of the novel p.Ala52Cysfs*9 and p.Lys1665Asn mutations found in patient 
P1
ATR  
and modelling these mutations in DT40 lymphocytes. 
A. Pictures of Seckel patient P1
ATR
. Patient shows typical Seckel features, including microcephaly, 
dysmorphic facial appearance and finger/toe abnormalities. B. Expression of the ATR protein in 
fibroblasts derived from patient P1
ATR
 and this patient’s mother (paternal cell line not available). ATR 
levels are analysed using the ATR-N19 antibody (Santa Cruz). SMC1 is used as loading control. C. 
Patient P1
ATR
 harbours compound heterozygous ATR mutations, including a known splicing mutation 
in one allele, plus a novel missense mutation of unknown effects in the other allele. The maternal 
allele carries a splicing mutation (c.151+4A>G) in intron 2, resulting in skipping of exon 2 and a 
truncated protein (p.Ala52Cysfs*9 ). The paternal allele harbours a point mutation in exon 28 
(c.4995G>T) that results in a missense mutation (p.Lys1665Asn). D. Sequencing of ATR exons 2 and 
28 from the mother of patient P1
ATR
 and the affected patient. The exon-intron boundaries are indicated 
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with a dashed line, while the mutated bases are shown below the ATR sequence E. Altered DNA 
damage signalling in fibroblast cell line derived from patient P1
ATR
. Phosphorylation of the ATR 
targets pCHK1-S345, pRPA2-S4/8 and γH2AX, as well as pSMC1-S966, pNBS1-S343. 
Corresponding total protein levels are used as loading control. F. A linear schematic of chicken Atr is 
shown, highlighting the HEAT repeat units (black/purple boxes), exons (in grey) and known domains 
that make up its structure. Overall identity between ATR/Atr proteins (amino acid level) is 77.2%. 
Residues mutated in patients are shown in yellow, while a single species-specific mismatch 8 amino 
acids C-terminal to Met1180 is shown in grey. G. Western blot analyses of total cell extracts prepared 
from DT40 cells expressing Atr, AID-Atr, Atr 
p.Met1180Ile
 and Atr 
p.Lys1685Asn
. Note that AID-Atr 
untreated sample is under loaded. H. Growth curve analysis of the Atr 
p.Met1180Ile
 and Atr 
p.Lys1685Asn
 cell 
lines following treatment with auxin (AUX). Error bars represent the SD from at least three 
independent experiments. I. Western analysis of Chk1-S345 phosphorylation. An antibody that 
recognises phosphorylation of CHK1 on S345 (Cell Signalling) was used to assess Atr function, while 
an antibody against total CHK1 (FL-476 Santa Cruz) was used as a loading control. J. Measurement 
of HU induced apoptosis in the indicated cell lines. Error bars in the graph represent the SD from 
three independent experiments. 
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Figure 2. ATR exon 18 and 28 skipping in patient 27-4BI and patient P1
ATR
, respectively.  
A. PCR analysis of cDNA isolated from LCLs derived from either an unaffected individual (WT) and 
patients 27-4BI (ATR c.3477G>T) or patient P1ATR (ATR c.4995G>T). B. Sequencing results for 
patient 27-4BI (ATR c.3477G>T) and P1ATR (ATR c.4995G>T). Upper and lower bands from A (no 
CHX) were sequenced. The chromatogram illustrates exon18 and exon 28 skipping in the shorter 
mRNA variants. C. PCR analysis of the mini-gene splicing assay performed in both HeLa and 
HEK293T cells. D. Sequencing results for patient 27-4BI (left panels) and patient P1
ATR
 (right 
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panels). The chromatogram demonstrates absence of exon 18 and exon 28, respectively, upon mini-
gene transfection and in vivo splicing of ATR constructs. E. Band shift assay using an RNA probe 
specific to the 9G8 splicing factor and competing RNA oligonucleotides specific to WT and mutated 
ATR exons 18. F. Band shift assay using an RNA probe specific to the 9G8 splicing factor and 
competing RNA oligonucleotides specific to WT and mutated ATR exons 28.  
 
 
 
